Advertisement

Clinical Rheumatology

, Volume 37, Issue 4, pp 1053–1058 | Cite as

Ischemic heart disease and ankylosing spondylitis—assessing the role of inflammation

  • Michal Vinker Shuster
  • Omer Gendelman
  • Shmuel Tiosano
  • Doron Comaneshter
  • Arnon D. Cohen
  • Howard Amital
Original Article
  • 162 Downloads

Abstract

To assess the association of ankylosing spondylitis (AS) and ischemic heart disease (IHD) compared to traditional cardiovascular (CV) risk factors. Primary care and hospital records of patients with AS were analyzed, using the largest health maintenance organization in Israel, the “Clalit” Health Services data. These patients were compared with age- and gender-matched controls regarding the proportion of IHD in a cross-sectional study. Parameters including socioeconomic status, body mass index (BMI), smoking habits, and coexistent medical conditions hypertension, hyperlipidemia, and diabetes mellitus (DM) - as well as the use of NSAIDs and anti-TNFs were also assessed. The study included 4076 AS patients compared to 20,290 age- and gender-matched controls without AS. The proportion of IHD was higher among AS patients as compared to controls (14.1 vs. 6.36%, respectively, p < 0.01) and patients treated with anti-TNFs had a lower risk for IHD compared to non-anti-TNF users. The proportion of hypertension, hyperlipidemia, DM, and smoking was also higher among AS patients. However, in multivariate analyses following adjustment to these risk factors, AS was not found to be associated with IHD nor anti-TNF therapy to be a protective factor. Patients with AS have more traditional CV risk factors, thus are in a higher risk for IHD. AS itself was not shown to be independently associated with IHD. These findings emphasize the multifactorial process leading to increased proportion of IHD among AS patients and the need for a stringent control of traditional risk factors in these patients.

Keywords

Ankylosing spondylitis Autoimmunity Ischemic heart disease Risk factors 

Notes

Compliance with ethical standards

The study was approved by the ethics committee of CHS, located in the Soroka Medical Center, Beer-Sheva, Israel.

Conflict of interest

Prof. Arnon Cohen: Relationships relevant to this manuscript: Prof. Arnon Cohen received research grants from Janssen, Novartis, AbbVie and Sanofi. Other relationships: In the last 3 years, Prof. Arnon Cohen served as a consultant, advisor or speaker to AbbVie; Amgen; Boehringer Ingelheim; Dexcel pharma; Janssen; Kamedis; Lilly; Neopharm; Novartis; Perrigo; Pfizer, Rafa, Sanofi, Sirbal; Taro. All other authors declares no conflict of interest.

References

  1. 1.
    Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A (2002) Ankylosing spondylitis: an overview. Ann Rheum Dis 61(suppl 3):iii8–iii18CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    El Maghraoui A (2011) Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. Eur J Intern Med 22(6):554–560CrossRefPubMedGoogle Scholar
  3. 3.
    Dean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ (2014) Global prevalence of ankylosing spondylitis. Rheumatology 53(4):650–657CrossRefPubMedGoogle Scholar
  4. 4.
    Elewaut D, Matucci-Cerinic M (2009) Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice. Rheumatology.  https://doi.org/10.1093/rheumatology/kep146
  5. 5.
    Ozkan Y (2016) Cardiac involvement in ankylosing spondylitis. J Clin Med Res 8(6):427–430CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Momeni M, Taylor N, Tehrani M (2011) Cardiopulmonary manifestations of ankylosing spondylitis. Int J Rheumatol 2011:1–6CrossRefGoogle Scholar
  7. 7.
    Bremander A, Petersson IF, Bergman S, Englund M (2011) Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res 63(4):550–556.  https://doi.org/10.1002/acr.20408 CrossRefGoogle Scholar
  8. 8.
    Han C, Robinson DW, Hackett MV, Paramore LC, Fraeman KH, Bala MV (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33(11):2167–2172PubMedGoogle Scholar
  9. 9.
    Nurmohamed MT, Van der Horst-Bruinsma I, Maksymowych WP (2012) Cardiovascular and cerebrovascular diseases in ankylosing spondylitis: current insights. Curr Rheumatol Rep 14(5):415–421.  https://doi.org/10.1007/s11926-012-0270-6 CrossRefPubMedGoogle Scholar
  10. 10.
    Mathieu S, Gossec L, Dougados M, Soubrier M (2011) Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res 63(4):557–563.  https://doi.org/10.1002/acr.20364 CrossRefGoogle Scholar
  11. 11.
    Chou C-H, Lin M-C, Peng C-L, Wu YC, Sung FC, Kao CH, Liu SH (2014) A nationwide population-based retrospective cohort study: increased risk of acute coronary syndrome in patients with ankylosing spondylitis. Scand J Rheumatol 43(2):132–136.  https://doi.org/10.3109/03009742.2013.822097 CrossRefPubMedGoogle Scholar
  12. 12.
    Mathieu S, Motreff P, Soubrier M (2010) Spondyloarthropathies: an independent cardiovascular risk factor? Joint Bone Spine 77(6):542–545CrossRefPubMedGoogle Scholar
  13. 13.
    Malesci D, Niglio A, Mennillo GA, Buono R, Valentini G, La Montagna G (2007) High prevalence of metabolic syndrome in patients with ankylosing spondylitis. Clin Rheumatol 26(5):710–714CrossRefPubMedGoogle Scholar
  14. 14.
    Divecha H, Sattar N, Rumley A, Cherry L, Lowe GDO, Sturrock R (2005) Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation. Clin Sci 109(2):171–176CrossRefPubMedGoogle Scholar
  15. 15.
    Peters MJ, Van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT (2004) Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 34(3):585–592Google Scholar
  16. 16.
    Murray CJL, Lopez AD (2013) Measuring the global burden of disease. N Engl J Med 369(5):448–457CrossRefPubMedGoogle Scholar
  17. 17.
    Wright KA, Crowson CS, Michet CJ, Matteson EL (2015) Time trends in incidence, clinical features, and cardiovascular disease in ankylosing spondylitis over three decades: a population-based study. Arthritis Care Res 67(6):836–841.  https://doi.org/10.1002/acr.22512 CrossRefGoogle Scholar
  18. 18.
    Ahmed N, Prior JA, Chen Y, Hayward R, Mallen CD, Hider SL (2016) Prevalence of cardiovascular-related comorbidity in ankylosing spondylitis, psoriatic arthritis and psoriasis in primary care: a matched retrospective cohort study. Clin Rheumatol 35(12):3069–3073.  https://doi.org/10.1007/s10067-016-3362-2 CrossRefPubMedGoogle Scholar
  19. 19.
    Eriksson JK, Jacobsson L, Bengtsson K, Askling J (2017) Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis? Ann Rheum Dis 76(2):364–370.  https://doi.org/10.1136/annrheumdis-2016-209315 CrossRefPubMedGoogle Scholar
  20. 20.
    Huang Y-P, Wang Y-H, Pan S-L (2013) Increased risk of ischemic heart disease in young patients with newly diagnosed ankylosing spondylitis—a population-based longitudinal follow-up study. PLoS One 8(5):e64155.  https://doi.org/10.1371/journal.pone.0064155 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Essers I, Stolwijk C, Boonen A, de Bruin ML, Bazelier MT, de Vries F, van Tubergen A (2016) Ankylosing spondylitis and risk of ischaemic heart disease: a population-based cohort study. Ann Rheum Dis 75(1):203–209.  https://doi.org/10.1136/annrheumdis-2014-206147 CrossRefPubMedGoogle Scholar
  22. 22.
    Kucuk A, Uğur Uslu A, Icli A, Cure E, Arslan S, Turkmen K, Toker A, Kayrak M (June 2016) The LDL/HDL ratio and atherosclerosis in ankylosing spondylitis. Z Rheumatol 76:58–63.  https://doi.org/10.1007/s00393-016-0092-4 CrossRefGoogle Scholar
  23. 23.
    Brophy S, Cooksey R, Atkinson M, Zhou SM, Husain MJ, Macey S, Rahman MA, Siebert S (2012) No increased rate of acute myocardial infarction or stroke among patients with ankylosing spondylitis—a retrospective cohort study using routine data. Semin Arthritis Rheum 42(2):140–145.  https://doi.org/10.1016/j.semarthrit.2012.02.008 CrossRefPubMedGoogle Scholar
  24. 24.
    Papagoras C, Markatseli TE, Saougou I, Alamanos Y, Zikou AK, Voulgari PV, Kiortsis DN, Drosos AA (2014) Cardiovascular risk profile in patients with spondyloarthritis. Joint Bone Spine 81(1):57–63.  https://doi.org/10.1016/j.jbspin.2013.03.019 CrossRefPubMedGoogle Scholar
  25. 25.
    Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N, Jara LJ, Abu-Shakra M, Meroni PL, Sherer Y (2005) Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112(21):3337–3347CrossRefPubMedGoogle Scholar
  26. 26.
    Hahn BH, Grossman J, Chen W, McMahon M (2007) The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 28(2):69–75CrossRefPubMedGoogle Scholar
  27. 27.
    Del Rincón I, Williams K, Stern MP, Freeman GL, O’leary DH, Escalante A (2003) Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 48(7):1833–1840CrossRefPubMedGoogle Scholar
  28. 28.
    Roman MJ, Shanker B-A, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE (2003) Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349(25):2399–2406CrossRefPubMedGoogle Scholar
  29. 29.
    Salmon JE, Roman MJ (2008) Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med 121(10):S3–S8CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Sari I, Okan T, Akar S, Cece H, Altay C, Secil M, Birlik M, Onen F, Akkoc N (2006) Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology 45(3):283–286CrossRefPubMedGoogle Scholar
  31. 31.
    Peters MJL, Smulders Y, Serne E, Dijkmans B, van der Horst-Bruinsma IE, Nurmohamed MT (2010) Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 37(1):161–166CrossRefPubMedGoogle Scholar
  32. 32.
    Van Eijk IC, Peters MJL, Serne EH et al (2009) Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor α blockade. Ann Rheum Dis 68(3):362–366CrossRefPubMedGoogle Scholar
  33. 33.
    Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B (2015) The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 74(3):480–489.  https://doi.org/10.1136/annrheumdis-2014-206624 CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Clegg DO (2006) Treatment of ankylosing spondylitis. J Rheumatol Suppl 33(78):24Google Scholar
  35. 35.
    Taurog JD, Chhabra A, Colbert RA (2016) Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med 374(26):2563–2574CrossRefPubMedGoogle Scholar
  36. 36.
    McGettigan P, Henry D (2011) Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 8(9):e1001098CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Bolten WW (2006) Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs. Ann Rheum Dis 65(1):7–13CrossRefPubMedGoogle Scholar
  38. 38.
    Peters MJL, Symmons DPM, McCarey D, Dijkmans BAC, Nicola P, Kvien TK, McInnes IB, Haentzschel H, Gonzalez-Gay MA, Provan S, Semb A, Sidiropoulos P, Kitas G, Smulders YM, Soubrier M, Szekanecz Z, Sattar N, Nurmohamed MT (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69(2):325–331CrossRefPubMedGoogle Scholar
  39. 39.
    Stagakis I, Bertsias G, Karvounaris S, Kavousanaki M, Virla D, Raptopoulou A, Kardassis D, Boumpas DT, Sidiropoulos PI (2012) Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. Arthritis Res Ther 14(3):R141CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Daïen CI, Duny Y, Barnetche T, Daurès J-P, Combe B, Morel J (2012) Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann Rheum Dis 71(6):862–868CrossRefPubMedGoogle Scholar
  41. 41.
    Westlake SL, Colebatch AN, Baird J, Curzen N, Kiely P, Quinn M, Choy E, Ostor AJK, Edwards CJ (2011) Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology 50(3):518–531CrossRefPubMedGoogle Scholar
  42. 42.
    Barnabe C, Martin B, Ghali WA (2011) Systematic review and meta-analysis: anti–tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res 63(4):522–529CrossRefGoogle Scholar
  43. 43.
    Tournadre A, Mathieu S, Soubrier M (2016) Managing cardiovascular risk in patients with inflammatory arthritis: practical considerations. Ther Adv Musculoskelet Dis 8(5):180–191.  https://doi.org/10.1177/1759720X16664306 CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Tiosano S, Yavne Y, Gendelman O, Watad A, Comaneshter D, Shoenfeld Y, Cohen AD, Amital D (2017) Stroke among rheumatoid arthritis patients: does age matter a real-life study. Neuroepidemiology 49(3–4):99–105.  https://doi.org/10.1159/000481992 CrossRefPubMedGoogle Scholar
  45. 45.
    Versini M, Tiosano S, Comaneshter D, Shoenfeld Y, Cohen AD, Amital H (April 2017) Smoking and obesity in systemic lupus erythematosus: a cross-sectional study. Eur J Clin Investig 47:422–427.  https://doi.org/10.1111/eci.12757 CrossRefGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2018

Authors and Affiliations

  • Michal Vinker Shuster
    • 1
    • 2
  • Omer Gendelman
    • 3
    • 4
  • Shmuel Tiosano
    • 3
    • 4
  • Doron Comaneshter
    • 5
  • Arnon D. Cohen
    • 5
    • 6
  • Howard Amital
    • 3
    • 4
  1. 1.The Hebrew University of JerusalemJerusalemIsrael
  2. 2.Hadassah Hebrew University Medical CenterJerusalemIsrael
  3. 3.Department of Medicine ‘B’, Zabludowicz Center for Autoimmune DiseasesSheba Medical CenterRamat-GanIsrael
  4. 4.Sackler Faculty of MedicineTel-Aviv UniversityTel-AvivIsrael
  5. 5.Chief Physician’s OfficeClalit Health ServicesTel AvivIsrael
  6. 6.Siaal Research Center for Family Medicine and Primary Care, Faculty of Health SciencesBen-Gurion University of the NegevBeer-ShevaIsrael

Personalised recommendations